Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Indiana University School of Medicine · Indiana University – Purdue University Indianapolis · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
704
total citations
- FWCI
- 69.17
- Percentile
- 100%
- References
- 31
Citations per year
Authors
19Topics & keywords
Topics
Keywords
- Boceprevir
- Ribavirin
- Medicine
- Internal medicine
- Gastroenterology
- Hepatitis C virus
- Clinical endpoint
- Hepatitis C
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.